TorsinA

Updated: 2026-09-17

Overview

TorsinA is a member of the AAA+ (ATPases Associated with diverse cellular Activities) superfamily, encoded by the TOR1A gene located on human chromosome 9q34. It plays a critical role in maintaining nuclear membrane integrity and endoplasmic reticulum (ER) function. The protein is ubiquitously expressed but has heightened significance in neuronal cells, where its dysfunction leads to DYT1 dystonia, a movement disorder characterized by involuntary muscle contractions. First identified in 1997, TorsinA's structure includes an N-terminal signal peptide, a central ATPase domain, and a C-terminal region. Wild-type TorsinA localizes to the ER lumen and nuclear envelope, while the pathogenic ΔE302/303 mutation causes aberrant perinuclear aggregation, disrupting cellular homeostasis.

Key Features

TorsinA operates as a molecular chaperone, facilitating the folding and degradation of misfolded proteins via ATP hydrolysis. Its interaction with cofactors like LAP1 and LULL1 modulates its ATPase activity and subcellular localization. Unlike typical AAA+ proteins, TorsinA lacks proteolytic activity but influences vesicular trafficking and lipid metabolism. The ΔE302/303 mutation, a deletion of a glutamic acid residue, impairs TorsinA's ATP-binding capacity, leading to toxic gain-of-function effects. This mutation is autosomal dominant, with only 30-40% penetrance, suggesting environmental or genetic modifiers. Research tools include knockout mice models and antibodies targeting specific epitopes for immunohistochemistry or Western blotting.

Application Areas

In biomedical research, TorsinA is studied for its role in dystonia pathogenesis and broader neuroprotective mechanisms. Investigations focus on how its mutation disrupts synaptic transmission and cytoskeletal dynamics, contributing to motor control deficits. High-throughput screens aim to identify small molecules that restore TorsinA function or mitigate mutant toxicity. Clinically, TorsinA serves as a biomarker for DYT1 dystonia diagnosis, though genetic testing remains the gold standard. Emerging therapies explore gene editing (e.g., CRISPR) and pharmacological chaperones. Industrial applications include recombinant protein production for antibody development and drug discovery platforms.

Precautions

Handling TorsinA reagents requires stringent protocols to prevent denaturation or contamination. Recombinant proteins should be aliquoted and stored at -80°C with protease inhibitors. Avoid repeated freeze-thaw cycles. For cell-based assays, ensure proper transfection controls to account for variable expression levels. Ethical considerations apply when using human-derived samples or genetic data. Compliance with institutional biosafety guidelines is mandatory, particularly for viral vectors in gene therapy research. Commercial antibodies should be validated for cross-reactivity with homologous proteins like TorsinB.

B2B Procurement Guide

Suppliers of TorsinA-related products include Thermo Fisher Scientific, Abcam, and Sigma-Aldrich, offering antibodies, ELISA kits, and recombinant proteins. Key procurement criteria include batch consistency, documentation (e.g., CoA), and technical support. Bulk orders may qualify for discounts, but verify lead times for custom services like epitope tagging. For specialized needs (e.g., mutant isoforms), consider contract research organizations (CROs) with gene synthesis capabilities. Pilot testing is advised to confirm product suitability. Logistics should prioritize cold-chain shipping, especially for live-cell assays or in vivo studies.